Preliminary Clinical Data from Ongoing Phase 1b/2a Clinical Program Presented at New Directions in Biology and Disease of Skeletal Muscle 6th Biennial Conference CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akashi Therapeutics, Inc. a clinical stage biopharmaceutical company developing treatments for patients with Duchenne muscular dystrophy (DMD), today reported that ...
With the HT-100, ANAVIA has developed the most advanced unmanned aerial vehicle (UAV) system in the world. An unmanned helicopter for up to 65 kg of payload and 240 minutes of flight time. It’s the ...
Scale model of HT-100 displayed at IDEX 2025. (Janes/Amit Kalra) Anavia, an Edge Group entity, exhibited a scale model of the naval version of its HT-100 unmanned aerial vehicle (UAV) at the ...
EDGE’s Swiss subsidiary Anavia has demonstrated what its parent company describes as a “complex flight profile” with an HT-100 unmanned air vehicle for the Brazilian armed forces and police. Recently ...
Halo Therapeutics announced that the FDA has granted orphan drug designation for HT-100 (halofuginone) for Duchenne muscular dystrophy (DMD). Plans to initiate a Phase 2 trial in 2012 are underway.
Investment from Muscular Dystrophy Association Adds to Funding from 15 Other Non-Profit Organizations CAMBRIDGE, MASS. — Akashi Therapeutics, Inc. announced today that the Muscular Dystrophy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results